148 related articles for article (PubMed ID: 28479198)
1. Sulfoximines as ATR inhibitors: Analogs of VE-821.
Hendriks CMM; Hartkamp J; Wiezorek S; Steinkamp AD; Rossetti G; Lüscher B; Bolm C
Bioorg Med Chem Lett; 2017 Jun; 27(12):2659-2662. PubMed ID: 28479198
[TBL] [Abstract][Full Text] [Related]
2. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
3. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
Charrier JD; Durrant SJ; Golec JM; Kay DP; Knegtel RM; MacCormick S; Mortimore M; O'Donnell ME; Pinder JL; Reaper PM; Rutherford AP; Wang PS; Young SC; Pollard JR
J Med Chem; 2011 Apr; 54(7):2320-30. PubMed ID: 21413798
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
6. Radio-sensitizing effects of VE-821 and beyond: Distinct phosphoproteomic and metabolomic changes after ATR inhibition in irradiated MOLT-4 cells.
Šalovská B; Janečková H; Fabrik I; Karlíková R; Čecháková L; Ondrej M; Link M; Friedecký D; Tichý A
PLoS One; 2018; 13(7):e0199349. PubMed ID: 30001349
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors.
Shaik A; Bhakuni R; Kirubakaran S
Molecules; 2018 Apr; 23(5):. PubMed ID: 29695073
[TBL] [Abstract][Full Text] [Related]
8. The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.
Moolmuang B; Ruchirawat M
J Pharm Pharmacol; 2021 Mar; 73(1):40-51. PubMed ID: 33791808
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of [
Carlucci G; Carney B; Sadique A; Vansteene A; Tang J; Reiner T
Nucl Med Biol; 2017 May; 48():9-15. PubMed ID: 28157626
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60).
Vávrová J; Zárybnická L; Lukášová E; Řezáčová M; Novotná E; Sinkorová Z; Tichý A; Pejchal J; Durišová K
Radiat Environ Biophys; 2013 Nov; 52(4):471-9. PubMed ID: 23934411
[TBL] [Abstract][Full Text] [Related]
11. Selective human inhibitors of ATR and ATM render Leishmania major promastigotes sensitive to oxidative damage.
da Silva RB; Machado CR; Rodrigues ARA; Pedrosa AL
PLoS One; 2018; 13(9):e0205033. PubMed ID: 30265735
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
Biskup E; Naym DG; Gniadecki R
J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitization of human leukemic HL-60 cells by ATR kinase inhibitor (VE-821): phosphoproteomic analysis.
Šalovská B; Fabrik I; Ďurišová K; Link M; Vávrová J; Řezáčová M; Tichý A
Int J Mol Sci; 2014 Jul; 15(7):12007-26. PubMed ID: 25003641
[TBL] [Abstract][Full Text] [Related]
14. Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
Knegtel R; Charrier JD; Durrant S; Davis C; O'Donnell M; Storck P; MacCormick S; Kay D; Pinder J; Virani A; Twin H; Griffiths M; Reaper P; Littlewood P; Young S; Golec J; Pollard J
J Med Chem; 2019 Jun; 62(11):5547-5561. PubMed ID: 31074988
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis.
Qi W; Xu X; Wang M; Li X; Wang C; Sun L; Zhao D; Sun L
Biochem Pharmacol; 2019 Jun; 164():273-282. PubMed ID: 31014753
[TBL] [Abstract][Full Text] [Related]
16. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
[TBL] [Abstract][Full Text] [Related]
17. ATR kinase inhibition sensitizes quiescent human cells to the lethal effects of cisplatin but increases mutagenesis.
Hutcherson RJ; Kemp MG
Mutat Res; 2019 Nov; 816-818():111678. PubMed ID: 31557599
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells.
Song N; Bai M; Che X; Li Z; Jing W; Li C; Teng Z; Qu X; Liu Y
Med Oncol; 2020 Apr; 37(5):47. PubMed ID: 32277292
[TBL] [Abstract][Full Text] [Related]
19. Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821.
Colis LC; Herzon SB
Bioorg Med Chem Lett; 2016 Jul; 26(13):3122-3126. PubMed ID: 27177826
[TBL] [Abstract][Full Text] [Related]
20. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
Prevo R; Fokas E; Reaper PM; Charlton PA; Pollard JR; McKenna WG; Muschel RJ; Brunner TB
Cancer Biol Ther; 2012 Sep; 13(11):1072-81. PubMed ID: 22825331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
